Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 24, Number 9—September 2018
Research

From Culturomics to Clinical Microbiology and Forward

On This Page
Materials and Methods
Results
Discussion
Cite This Article
Figures
Figure
Tables
Table 1
Table 2
Table 3
Table 4
Downloads
Article
RIS [TXT - 2 KB]
Article Metrics
Metric Details
21
citations of this article
EID Journal Metrics on Scopus
Author affiliations: Aix Marseille University, Institut de Recherche pour le Développement (IRD), Assistance Publique des Hôpitaux de Marseille (APHM), Microbes, Evolution, Phylogeny and Infections (MEPHI), Institut Hospitalo-Universitaire (IHU) Méditerranée Infection, Marseille, France (G. Dubourg, S. Baron, J.-C. Lagier, D. Raoult); APHM, IHU Méditerranée Infection, Marseille (F. Cadoret, C. Couderc); Aix Marseille University, IRD, APHM, Vecteurs–Infections Tropicales et Méditerranéennes, IHU Méditerranée Infection, Marseille (P.-E. Fournier)

Cite This Article

Abstract

Culturomics has permitted discovery of hundreds of new bacterial species isolated from the human microbiome. Profiles generated by using matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry have been added to the mass spectrometer database used in clinical microbiology laboratories. We retrospectively collected raw data from MALDI-TOF mass spectrometry used routinely in our laboratory in Marseille, France, during January 2012–March 2018 and analyzed 16S rDNA sequencing results from misidentified strains. During the study period, 744 species were identified from clinical specimens, of which 21 were species first isolated from culturomics. This collection involved 105 clinical specimens, accounting for 98 patients. In 64 cases, isolation of the bacteria was considered clinically relevant. MALDI-TOF mass spectrometry was able to identify the species in 95.2% of the 105 specimens. While contributing to the extension of the bacterial repertoire associated with humans, culturomics studies also enlarge the spectrum of prokaryotes involved in infectious diseases.

The diagnosis of bacterial diseases in clinical microbiology has relied on phenotypic identification, based on the bacterial repertoire known to be associated with humans. This mode of identification, which is, in fact, recognition of previously described microorganisms, does not allow for the identification of new bacteria. Recently, the systematic use of universal 16S rDNA gene sequencing of cultivated bacteria that presented an atypical phenotypical profile paved the way for identifying rare, fastidious, and new microorganisms (1,2). However, this method implies redefining specific phenotypical characteristics, which sometimes cannot be done because of the limited number of available biochemical tests. More recently, the revolution provided by matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry identification permits comparison of a protein spectrum obtained from a colony with a database, which can be permanently incremented with newly identified bacteria (3,4). The use of a cutoff identification score, with values in the range of 1.7–2, enables correct identification of the isolate. However, when MALDI-TOF mass spectrometry recognizes bacteria never previously associated with humans, it is reasonable to carry out confirmation by sequencing the 16S rDNA gene. The main advantage of MALDI-TOF mass spectrometry compared with sequencing methods is that it is extremely fast and cost-effective (3,4). Indeed, the cost involves mainly the cost of the machine; the individual cost per test is insignificant. Thus, the ease in testing bacterial colonies led us to establish the repertoire of commensal bacteria of the human microbiota in the laboratory at IHU Méditerranée Infection in Marseille, France, by using a high-throughput culture and MALDI-TOF mass spectrometry identification. Sequencing of the 16S rDNA gene enables identification of atypical bacteria with definition of new bacterial species, whose genomes are then sequenced. This approach, called culturomics (5,6), has made possible the addition of 672 bacteria to the known repertoire of the bacteria already isolated from the human mucosa. Other teams, in parallel, have used similar approaches (7,8).

The usefulness of culturomics in increasing knowledge of the repertoire of cultivable bacteria from human mucous membranes appears clear for microbiota studies. However, the benefit of this process in clinical microbiology is prone to controversy. We speculated that commensal bacteria found in humans may be involved in opportunistic infections. In our experience, the creation of new spectra enabled us to increment our MALDI-TOF mass spectrometry database used for clinical microbiology, thus enabling recognition of bacterial species first isolated as a part of culturomics studies and improving the accuracy of diagnosis of infectious diseases involving bacteria.

Materials and Methods

Settings

All data included in this study were obtained from the routine microbiology laboratory at IHU Méditerranée Infection, which receives a mean annual number of 350,400 samples from the 4 Marseille university hospitals (Timone, Conception, North, and Sainte-Marguerite hospitals), which contain a total of 3,700 beds. Retrospective data were collected for January 2012–March 2018.

Routine Bacteriological Practices

We analyzed samples according to standard microbiological procedures, as previously described, depending on the specimen (9–12). This process included systematic inoculation onto Columbia agar with 5% sheep blood (BioMérieux, Craponne, France), chocolate agar (BioMérieux) (excluding urine and fecal samples), and specific media such as colistin-nalidixic agar or MacConkey agar (both BioMérieux) for specimens potentially contaminated by resident flora. Blood cultures were incubated into a Bactec device (Becton Dickinson, Le Pont de Claix, France) and analyzed as previously described (9).

Specific Cultures

We plated fecal specimens taken following a regional outbreak of Clostridioides (formerly Clostridium) difficile 027 during May 2013–March 2018 (13), in which toxin detection was positive using GeneXpert C. difficile PCR (Cepheid, Paris, France) after ethanol treatment (14), to obtain C. difficile isolates. We also investigated possible multidrug-resistant bacteria carriage by plating on chromID MRSA agar for methicillin-resistant Staphylococcus aureus, chromID CARBA SMART medium (BioMérieux) for carbapenemase-producing Enterobacteriaceae (CPE), and Drigalski/MacConkey agar (BioMérieux) for third-generation, cephalosporin-resistant, gram-negative bacteria.

Identification of Colonies

We performed bacterial identification on colonies using MALDI-TOF mass spectrometry, as previously described (3,4). We considered identification to be correct when the identification score was >1.9 and when the same single species was recognized. When identification did not meet these criteria, we performed proteic extraction using formic acid and acetonitrile (15). If identification was still incorrect following the proteic extraction protocol, we performed 16S rDNA sequencing systematically, as previously described (16), in 3 situations: when the identification score was <1.9 despite proteic extraction, when multiple different species were recognized with a correct identification score, and when a bacterium was isolated for the first time in the clinical microbiology laboratory.

Culturomics Studies

In brief, culturomics consists of the multiplication of culture conditions applied to human specimens to increase the repertoire of the human microbiome. The pioneering study used 212 conditions (5); this number was reduced to 70 in 2012 (17,18) and then to 18 in 2014 (6). In addition, several specific conditions were designed for archaea, microcolonies, proteobacteria, and microaerophilic and halophilic bacteria. Most specimens used were fecal samples. However, respiratory, vaginal, and urine samples have been analyzed recently in the context of culturomics studies. Identification has also been performed using MALDI-TOF mass spectrometry. Colonies were considered correctly identified when 2 colonies exhibited an identification score >1.9. If identification scores were not correct after 3 attempts, sequencing of the 16S rDNA gene was performed (16). If there was <98.7% similarity with the closest neighbor, the bacterial isolate was considered to be a new species (19).

Updating the MALDI-TOF Mass Spectrometry Database

The database used for routine bacterial identification is updated through 3 sources: updates from the MALDI-TOF mass spectrometry manufacturer, updates from culturomics studies, and routine laboratory results. Updates from culturomics studies and routine laboratory results are based on 16S rDNA sequencing results.

Analysis of Data from MALDI-TOF Mass Spectrometry Used in the Clinical Microbiology Laboratory

We retrospectively collected raw data from MALDI-TOF mass spectrometry used in the microbiology laboratory involving identifications performed during January 2012–March 2018, which are saved monthly. Data were deduced from the samples. These data do not consider the clinical relevance of the identified microorganism, the final result, or multiple attempts to identify the colony using MALDI-TOF mass spectrometry.

Results

Bacterial Identification in Clinical Microbiology Laboratory

Figure

Thumbnail of Annual ratio of unidentified bacteria and evolution of the number of spectral references available in the matrix-assisted laser desorption/ionization time-of-flight mass spectrometry database in a clinical laboratory in Marseille, France.

Figure. Annual ratio of unidentified bacteria and evolution of the number of spectral references available in the matrix-assisted laser desorption/ionization time-of-flight mass spectrometry database in a clinical laboratory in Marseille, France.

During January 2012–March 2018, the clinical microbiology laboratory performed 351,937 nondereplicated bacterial identifications using MALDI-TOF mass spectrometry. Of these, 28,391 (8.1%) were unidentified or misidentified. When we looked at the yearly ratio of unidentified bacteria, we noticed that it fell from 17.7% in 2012 to 3.6% in 2018 (Figure). Overall, we identified 744 unique bacterial species correctly using MALDI-TOF mass spectrometry.

Contribution to MALDI-TOF Mass Spectrometry Database Updates

During the study period, we added 4,539 references to our database. Updates from the manufacturer comprised 3,255 references, whereas 983 references came from routine laboratory results. In addition, 306 (23.4%) updates were from new bacterial species discovered as a part of culturomics studies. Overall, references from the manufacturer represented 87% of the total database, routine laboratory results represented 8%, and new culturomics species represented 5% (Figure).

Routine Identification of Species Isolated as Part of Culturomics Studies

Among the 351,937 bacterial identifications performed routinely during the study period, we identified species first isolated from culturomics studies in 105 clinical specimens, accounting for 98 patients. This collection represents a total of 21 species, accounting for 2.8% (21/744) of the overall microbiology laboratory bacterial diversity (Table 1).

Among the 105 colonies identified as new species isolated as a part of culturomics studies, identification was correct for 100 (95.2%) using MALDI-TOF mass spectrometry. Thus, 16S rDNA gene sequencing was required for 5 strains to achieve final identification. MALDI-TOF mass spectrometry was not able to provide a reliable identification for Varibaculum timonense, Prevotella ihuae, Actinomyces ihuae, and 2 Corynebacterium phoceense isolates. We confirmed identification of 9 supplementary strains, representing 5 species (Corynebacterium lascolaense, Actinomyces ihuae, Corynebacterium ihuae, Nosocomiicoccus massiliensis, and Pseudomonas massiliensis), using 16S rDNA gene sequencing (Tables 2,3). Overall, we sequenced 14 isolates, accounting for 8 species, for the 16S rDNA gene.

Species Potentially Relevant as Human Pathogens

Among the 105 isolates included in this work, 64 were isolated as potential pathogens, accounting for 14 different species. Most were anaerobes that were cultured from abscesses or punctures, often involved in cases of polymicrobial infections. Peptoniphilus grossensis (18 cases) and Actinomyces ihuae (17 cases) were the most commonly isolated bacteria (Table 1). These species were initially cultured from the human gut. Special attention was given to A. ihuae infections (Table 4), which were strongly associated with breast abscess or genital area infections. Also, 10 bacteremia-involved species were isolated as a part of culturomics studies. Bacteroides timonensis was thus isolated in 3 blood cultures from 2 patients, whereas Pseudomonas massiliensis was found in 3 bacteremia episodes. Corynebacterium phoceense and Corynebacterium ihuae were recovered from 2 bloodstream infection episodes, whereas Actinomyces marseillensis and Nosocomicoccus massiliensis were each isolated from 1 blood sample (from 2 different patients). B. timonensis, P. massiliensis, N. massiliensis, and C. ihuae were first cultured from the human gut, whereas A. marseillensis was first isolated from respiratory microbiota and C. phoceense was first isolated from urinary microbiota. Overall, species cultured as part of culturomics studies were found to be potential pathogens in 59 different patients (Table 2). The significance of the presence of P. massiliensis in a lens from a patient with keratitis was ultimately not interpreted.

Species Isolated as Human Commensal Members

In this work, 40 isolates corresponding to 12 species discovered as a part of culturomics studies were isolated as belonging to the human flora. Of these, 22 were recovered when evaluating for toxigenic C. difficile, following a positive result with the GeneXpert C. difficile test. C. saudii was isolated in this context 11 times, followed by C. jeddahtimonense (8 times), C. culturomicsense, Butyricimonas phocaeensis, and Anaerosalibacter massiliensis (1 time each) (Table 3). These 5 species were first cultured from fecal specimens (Table 1).

In addition, Corynebacterium lascolaense was identified in 1 urine specimen, but in an insufficient quantity to be considered clinically relevant. Similarly, C. phoceense was recovered from 1 urine sample and from 7 vaginal swabs but was never reported to a physician in this context. These species were first cultured from urinary microbiota. Finally, Pseudomonas massiliensis, which was cultured from the human gut, was also recovered twice from skin swabs collected from the same physician after an epidemiologic investigation. Overall, species cultured for the first time as a part of culturomics studies were found as commensals in 38 different patients.

Discussion

This work constitutes the proof of concept that exploration of the repertoire of commensal bacteria enables identification of microorganisms involved in clinical microbiology. Indeed, the strategy of combining high-throughput culture techniques, MALDI-TOF mass spectrometry identification, and 16S rDNA gene sequencing of misidentified isolates enabled us to add 306 spectral references for 292 different new bacterial species to our laboratory’s database. Thus, with culturomics, 21 new species were identified 105 times, in 98 patients. The results are robust; identification scores were all >1.9 with exclusion of multiple identifications. In addition, identification of 9 strains using 16S rDNA sequencing, accounting for 5 species, confirmed the initial recognition by MALDI-TOF mass spectrometry (Table 2). These results strengthen our belief that identifying commensal microbes provides a valuable contribution to clinical microbiology, as revealed by the decrease in the number of unidentified colonies by MALDI-TOF mass spectrometry over time (Figure).

As exemplified for A. ihuae infections (Table 4), these microorganisms, which were isolated mainly from the human gut, can probably be found frequently in polymicrobial cultures. Thus, the microbiologist may be tempted to abandon the final identification of a microorganism found in such a situation, concluding that the infection is polymicrobial.

The extension of the bacterial repertoire associated with humans will considerably increase the number of bacteria associated with human diseases. In this study alone, over a 5-year period, 2.8% (21/744) of the overall identified bacteria would not have been identified without incrementing the MALDI-TOF mass spectrometry database with spectra obtained from culturomics studies.

On the whole, pathogenic microbes are also often found as commensals, as is currently well known for C. difficile, S. aureus, and S. pneumoniae (35–37). In our study, for example, Corynebacterium phoceense, Pseudomonas massiliensis, and C. lascolaense were found as both commensals and pathogens. This finding highlights the need for establishment of a repertoire of human microbes (38), which was recently estimated at 2,776 species, of which more than 10% were recovered by culturomics studies. Such a repertoire of prokaryotes associated with humans not only benefits microbiota studies, through notation of unknown sequences with new species genome sequencing, but also enables studying the role of these species in human infections (39). We estimate that, among the cases included here, the presence of species cultured as part of culturomics studies was potentially clinically relevant for 60 of them (61.2%). The online availability of the MALDI-TOF mass spectrometry spectra obtained from these species discovered by culturomics (http://www.mediterranee-infection.com/article.php?laref=256&titre=urms-database) ensures their further identification by other laboratories.

Culturomics was initially designed to exhaustively identify commensals inhabiting human surfaces and thus can potentially lead in the future to personal medical interventions as a part of microbiome studies. However, the thinnest barrier between commensalism and pathogenicity, which should lead researchers to rethink Koch’s postulate (40), has rendered culturomics studies useful in the field of clinical microbiology despite a potential skepticism. We show herein that, while contributing to the extension of the bacterial repertoire associated with humans, culturomics studies also enlarge the spectrum of prokaryotes involved in infectious diseases.

Dr. Dubourg is an assistant professor of bacteriology at IHU Méditerranée Infection, Marseille, France. His primary research interest is human microbiome studies.

Top

Acknowledgment

This work has benefited from French state support, managed by the Agence Nationale pour la Recherche, including the Programme d’Investissement d’Avenir under the reference Méditerranée Infection 10-IAHU-03. This work was also supported by Région Provence Alpes Côte d’Azur and Fonds Européen de Développement Regional—Plateformes de Recherche et d'Innovation Mutualisées Méditerranée Infection (FEDER PRIMI).

Top

References

  1. Drancourt  M, Berger  P, Raoult  D. Systematic 16S rRNA gene sequencing of atypical clinical isolates identified 27 new bacterial species associated with humans. J Clin Microbiol. 2004;42:2197–202. DOIPubMedGoogle Scholar
  2. Drancourt  M, Bollet  C, Carlioz  A, Martelin  R, Gayral  JP, Raoult  D. 16S ribosomal DNA sequence analysis of a large collection of environmental and clinical unidentifiable bacterial isolates. J Clin Microbiol. 2000;38:3623–30.PubMedGoogle Scholar
  3. Clark  AE, Kaleta  EJ, Arora  A, Wolk  DM. Matrix-assisted laser desorption ionization-time of flight mass spectrometry: a fundamental shift in the routine practice of clinical microbiology. Clin Microbiol Rev. 2013;26:547–603. DOIPubMedGoogle Scholar
  4. Seng  P, Drancourt  M, Gouriet  F, La Scola  B, Fournier  PE, Rolain  JM, et al. Ongoing revolution in bacteriology: routine identification of bacteria by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Clin Infect Dis. 2009;49:543–51. DOIPubMedGoogle Scholar
  5. Lagier  JC, Armougom  F, Million  M, Hugon  P, Pagnier  I, Robert  C, et al. Microbial culturomics: paradigm shift in the human gut microbiome study. Clin Microbiol Infect. 2012;18:1185–93. DOIPubMedGoogle Scholar
  6. Lagier  JC, Khelaifia  S, Alou  MT, Ndongo  S, Dione  N, Hugon  P, et al. Culture of previously uncultured members of the human gut microbiota by culturomics. Nat Microbiol. 2016;1:16203. DOIPubMedGoogle Scholar
  7. Goodman  AL, Kallstrom  G, Faith  JJ, Reyes  A, Moore  A, Dantas  G, et al. Extensive personal human gut microbiota culture collections characterized and manipulated in gnotobiotic mice. Proc Natl Acad Sci U S A. 2011;108:6252–7. DOIPubMedGoogle Scholar
  8. Browne  HP, Forster  SC, Anonye  BO, Kumar  N, Neville  BA, Stares  MD, et al. Culturing of ‘unculturable’ human microbiota reveals novel taxa and extensive sporulation. Nature. 2016;533:543–6. DOIPubMedGoogle Scholar
  9. Gouriet  F, Million  M, Henri  M, Fournier  PE, Raoult  D. Lactobacillus rhamnosus bacteremia: an emerging clinical entity. Eur J Clin Microbiol Infect Dis. 2012;31:2469–80. DOIPubMedGoogle Scholar
  10. Dubourg  G, Delord  M, Gouriet  F, Fournier  PE, Drancourt  M. Actinomyces gerencseriae hip prosthesis infection: a case report. J Med Case Reports. 2015;9:223. DOIPubMedGoogle Scholar
  11. Levy  PY, Fournier  PE, Fenollar  F, Raoult  D. Systematic PCR detection in culture-negative osteoarticular infections. Am J Med. 2013;126:1143.e25–33. DOIPubMedGoogle Scholar
  12. Dubourg  G, Abat  C, Rolain  JM, Raoult  D. Correlation between sputum and bronchoalveolar lavage fluid cultures. J Clin Microbiol. 2015;53:994–6. DOIPubMedGoogle Scholar
  13. Cassir  N, Delarozière  JC, Dubourg  G, Delord  M, Lagier  JC, Brouqui  P, et al. A regional outbreak of Clostridium difficile PCR-ribotype 027 infections in southeastern France from a single long-term care facility. Infect Control Hosp Epidemiol. 2016;37:1337–41. DOIPubMedGoogle Scholar
  14. Marler  LM, Siders  JA, Wolters  LC, Pettigrew  Y, Skitt  BL, Allen  SD. Comparison of five cultural procedures for isolation of Clostridium difficile from stools. J Clin Microbiol. 1992;30:514–6.PubMedGoogle Scholar
  15. El Khéchine  A, Couderc  C, Flaudrops  C, Raoult  D, Drancourt  M. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry identification of mycobacteria in routine clinical practice. PLoS One. 2011;6:e24720. DOIPubMedGoogle Scholar
  16. Morel  AS, Dubourg  G, Prudent  E, Edouard  S, Gouriet  F, Casalta  JP, et al. Complementarity between targeted real-time specific PCR and conventional broad-range 16S rDNA PCR in the syndrome-driven diagnosis of infectious diseases. Eur J Clin Microbiol Infect Dis. 2015;34:561–70. DOIPubMedGoogle Scholar
  17. Dubourg  G, Lagier  JC, Robert  C, Armougom  F, Hugon  P, Metidji  S, et al. Culturomics and pyrosequencing evidence of the reduction in gut microbiota diversity in patients with broad-spectrum antibiotics. Int J Antimicrob Agents. 2014;44:117–24. DOIPubMedGoogle Scholar
  18. Pfleiderer  A, Lagier  JC, Armougom  F, Robert  C, Vialettes  B, Raoult  D. Culturomics identified 11 new bacterial species from a single anorexia nervosa stool sample. Eur J Clin Microbiol Infect Dis. 2013;32:1471–81. DOIPubMedGoogle Scholar
  19. Rossi-Tamisier  M, Benamar  S, Raoult  D, Fournier  P-E. Cautionary tale of using 16S rRNA gene sequence similarity values in identification of human-associated bacterial species. Int J Syst Evol Microbiol. 2015;65:1929–34. DOIPubMedGoogle Scholar
  20. Ndongo  S, Khelaifia  S, Bittar  F, Fournier  P-E, Raoult  D. “Actinomyces ihumii,” a new bacterial species isolated from the digestive microbiota of a HIV-infected patient. New Microbes New Infect. 2016;12:71–2. DOIPubMedGoogle Scholar
  21. Fonkou  MDM, Bilen  M, Cadoret  F, Fournier  PE, Dubourg  G, Raoult  D. ‘Enterococcus timonensis’ sp. nov., ‘Actinomyces marseillensis’ sp. nov., ‘Leptotrichia massiliensis’ sp. nov., ‘Actinomyces pacaensis’ sp. nov., ‘Actinomyces oralis’ sp. nov., ‘Actinomyces culturomici’ sp. nov. and ‘Gemella massiliensis’ sp. nov., new bacterial species isolated from the human respiratory microbiome. New Microbes New Infect. 2017;22:37–43. DOIPubMedGoogle Scholar
  22. Lagier  JC, Bibi  F, Ramasamy  D, Azhar  EI, Robert  C, Yasir  M, et al. Non contiguous-finished genome sequence and description of Clostridium jeddahense sp. nov. Stand Genomic Sci. 2014;9:1003–19. DOIPubMedGoogle Scholar
  23. Dione  N, Sankar  SA, Lagier  JC, Khelaifia  S, Michele  C, Armstrong  N, et al. Genome sequence and description of Anaerosalibacter massiliensis sp. nov. New Microbes New Infect. 2016;10:66–76. DOIPubMedGoogle Scholar
  24. Ramasamy  D, Lagier  JC, Rossi-Tamisier  M, Pfleiderer  A, Michelle  C, Couderc  C, et al. Genome sequence and description of Bacteroides timonensis sp. nov. Stand Genomic Sci. 2014;9:1181–97. DOIPubMedGoogle Scholar
  25. Togo  AH, Diop  A, Dubourg  G, Nguyen  TT, Andrieu  C, Caputo  A, et al. Butyricimonas phoceensis sp. nov., a new anaerobic species isolated from the human gut microbiota of a French morbidly obese patient. New Microbes New Infect. 2016;14:38–48. DOIPubMedGoogle Scholar
  26. Pham  TP, Cadoret  F, Tidjani Alou  M, Brah  S, Ali Diallo  B, Diallo  A, et al. ‘Marasmitruncus massiliensis’ gen. nov., sp. nov., ‘Clostridium culturomicum’ sp. nov., ‘Blautia provencensis’ sp. nov., ‘Bacillus caccae’ sp. nov. and ‘Ornithinibacillus massiliensis’ sp. nov., isolated from stool samples of undernourished African children. New Microbes New Infect. 2017;19:38–42. DOIPubMedGoogle Scholar
  27. Angelakis  E, Bibi  F, Ramasamy  D, Azhar  EI, Jiman-Fatani  AA, Aboushoushah  SM, et al. Non-contiguous finished genome sequence and description of Clostridium saudii sp. nov. Stand Genomic Sci. 2014;9:8. DOIPubMedGoogle Scholar
  28. Padmanabhan  R, Dubourg  G, Lagier  JC, Couderc  C, Michelle  C, Raoult  D, et al. Genome sequence and description of Corynebacterium ihumii sp. nov. Stand Genomic Sci. 2014;9:1128–43. DOIPubMedGoogle Scholar
  29. Cresci  M, Ibrahima Lo  C, Khelaifia  S, Mouelhi  D, Delerce  J, Di Pinto  F, et al. Corynebacterium phoceense sp. nov., strain MC1T a new bacterial species isolated from human urine. New Microbes New Infect. 2016;14:73–82. DOIPubMedGoogle Scholar
  30. Mourembou  G, Rathored  J, Ndjoyi-Mbiguino  A, Lekana-Douki  JB, Fenollar  F, Robert  C, et al. Noncontiguous finished genome sequence and description of Gabonia massiliensis gen. nov., sp. nov. New Microbes New Infect. 2015;9:35–44. DOIPubMedGoogle Scholar
  31. Mishra  AK, Edouard  S, Dangui  NP, Lagier  JC, Caputo  A, Blanc-Tailleur  C, et al. Non-contiguous finished genome sequence and description of Nosocomiicoccus massiliensis sp. nov. Stand Genomic Sci. 2013;9:205–19. DOIPubMedGoogle Scholar
  32. Mishra  AK, Hugon  P, Robert  C, Raoult  D, Fournier  PE. Non contiguous-finished genome sequence and description of Peptoniphilus grossensis sp. nov. Stand Genomic Sci. 2012;7:320–30. DOIPubMedGoogle Scholar
  33. Guilhot  E, Lagier  JC, Raoult  D, Khelaifia  S. ‘Prevotella ihumii’ sp. nov. and ‘Varibaculum timonense’ sp. nov., two new bacterial species isolated from a fresh human stool specimen. New Microbes New Infect. 2017;18:3–5. DOIPubMedGoogle Scholar
  34. Bardet  L, Cimmino  T, Buffet  C, Michelle  C, Rathored  J, Tandina  F, et al. Microbial culturomics application for global health: noncontiguous finished genome sequence and description of Pseudomonas massiliensis strain CB-1T sp. nov. in Brazil. OMICS. 2018;22:164–75. DOIPubMedGoogle Scholar
  35. Zhang  L, Dong  D, Jiang  C, Li  Z, Wang  X, Peng  Y. Insight into alteration of gut microbiota in Clostridium difficile infection and asymptomatic C. difficile colonization. Anaerobe. 2015;34:1–7. DOIPubMedGoogle Scholar
  36. Mendy  A, Vieira  ER, Albatineh  AN, Gasana  J. Staphylococcus aureus colonization and long-term risk for death, United States. Emerg Infect Dis. 2016;22:1966–9. DOIPubMedGoogle Scholar
  37. Lewnard  JA, Huppert  A, Givon-Lavi  N, Pettigrew  MM, Regev-Yochay  G, Dagan  R, et al. Density, serotype diversity, and fitness of Streptococcus pneumoniae in upper respiratory tract cocolonization with nontypeable Haemophilus influenzae. J Infect Dis. 2016;214:1411–20. DOIPubMedGoogle Scholar
  38. Bilen  M, Dufour  JC, Lagier  JC, Cadoret  F, Daoud  Z, Dubourg  G, et al. The contribution of culturomics to the repertoire of isolated human bacterial and archaeal species. Microbiome. 2018;6:94. DOIPubMedGoogle Scholar
  39. Lagier  JC, Dubourg  G, Million  M, Cadoret  F, Bilen  M, Fenollar  F, et al. Culturing the human microbiota and culturomics. Nat Rev Microbiol. 2018;16:540–50. DOIPubMedGoogle Scholar
  40. Lagier  JC, Dubourg  G, Amrane  S, Raoult  D. Koch postulate: why should we grow bacteria? Arch Med Res. 2017;48:774–9. DOIPubMedGoogle Scholar

Top

Figure
Tables

Top

Cite This Article

DOI: 10.3201/eid2409.170995

Table of Contents – Volume 24, Number 9—September 2018

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.

Top

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Didier Raoult, IHU Méditerranée Infection, 19-21 Boulevard Jean Moulin, 13385 Marseille CEDEX 5, France

Send To

10000 character(s) remaining.

Top

Page created: August 14, 2018
Page updated: August 14, 2018
Page reviewed: August 14, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external